Treatment with biologic response modifiers in patients with ovarian cancer.

Koelbl, H; Micksche, M; Gitsch, G; Hanzal, E; Nowotny, C

Koelbl, H; Micksche, M; Gitsch, G; Hanzal, E; Nowotny, C.

Affiliation

Koelbl H; 2nd Department Obstetrics and Gynecology, University Hospital of Vienna, Austria.

Eur J Obstet Gynecol Reprod Biol ; 41(1): 64-9, 1991 Aug 20.

Article in En | MEDLINE | ID: mdl-1748228

Subject(s)

Immunologic Factors/therapeutic use; Interferon-gamma/therapeutic use; Ovarian Neoplasms/therapy; Picibanil/therapeutic use; Aged; Ascitic Fluid/drug therapy; Ascitic Fluid/pathology; Cytotoxicity, Immunologic/drug effects; Female; Humans; Injections, Intraperitoneal; Interferon-gamma/adverse effects; Killer Cells, Natural/drug effects; Macrophages/drug effects; Middle Aged; Ovarian Neoplasms/complications; Pleural Effusion/drug therapy; Pleural Effusion/pathology; Recombinant Proteins/adverse effects; Recombinant Proteins/therapeutic use

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Ovarian Neoplasms / Picibanil / Interferon-gamma / Immunologic Factors Limits: Aged / Female / Humans / Middle aged Language: En Year: 1991 Type: Article

Search on Google

XML

PubMed Links